EU extends safety review of chronic Hep C treatments

The European health regulator said it extended a safety review of chronic hepatitis C treatments after new data showed patients taking the drugs were at risk of their liver cancer returning. "The study suggested that these patients were at risk of their cancer coming back earlier than patients with hepatitis C who were not treated with direct-acting antivirals," the European Medicines Agency (EMA) said. (bit.ly/1MxDslL) The review covers some of the